Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Eli Muchtar, Prashant Kapoor et al.|Blood Neoplasia|2025Cited by 18
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Shaji Kumar, Dragan Jevremović et al.|Blood Cancer Journal|2025Cited by 8